HC Wainwright Has Lowered Expectations for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target cut by HC Wainwright from $20.00 to $10.00 in a research note published on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms have also recently commented on ZNTL. Guggenheim decreased their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Wedbush restated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Finally, UBS Group decreased their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.58.

Zentalis Pharmaceuticals Stock Down 21.3 %

Shares of NASDAQ:ZNTL opened at $1.89 on Wednesday. The firm’s 50 day simple moving average is $3.00 and its 200-day simple moving average is $3.30. Zentalis Pharmaceuticals has a one year low of $1.76 and a one year high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. As a group, equities analysts expect that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ZNTL. Erste Asset Management GmbH acquired a new stake in Zentalis Pharmaceuticals in the 3rd quarter worth about $37,000. Paloma Partners Management Co purchased a new stake in Zentalis Pharmaceuticals in the 3rd quarter valued at $37,000. Aigen Investment Management LP purchased a new stake in shares of Zentalis Pharmaceuticals in the third quarter valued at about $41,000. Capstone Investment Advisors LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter worth approximately $48,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Zentalis Pharmaceuticals by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after acquiring an additional 5,333 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.